ReviewJournal of cellular and molecular medicine2026
AP-1-Targeting Decoy Oligonucleotides: Mechanisms and Therapeutic Potential as Modulators of Inflammatory Pathways.
Review in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoy oligonucleotide technology in cancer therapy: molecular mechanisms, challenges, and translational potential.Medical oncology (Northwood, London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Numerous cellular functions, such as apoptosis, proliferation, differentiation, survival, transformation and cell migration, are regulated by a crucial transcription factor called activator protein 1 (AP-1). Growing evidence indicates that AP-1 is involved in severe conditions like fibrosis, cancer, and organ damage, as well as inflammatory diseases, including rheumatoid arthritis, psoriasis, and asthma. In recent years, AP-1 has become a significant focus in drug research. The activation of AP-1 by TNF is crucial for essential components of the inflammatory reaction, including the expression of tissue remodelling proteases such as collagenase, as well as pro-inflammatory cell adhesion molecules like E-selectin. This transcription factor is formed by the assembly of jun-jun homodimers, jun-fos heterodimers, and jun-ATF (Activating Transcription Factor) heterodimers. As a member of the basic leucine zipper (bZIP) class, AP-1 regulates target genes by binding to their promoters in a sequence-specific way. New research suggests that reducing AP-1 function could improve various disease outcomes and treatments. Transfection of decoy oligonucleotides (ODNs) offers an innovative approach to gene therapy by targeting specific gene regulatory elements. Transcription factor decoys mimic the sites where transcription factors bind, competing with promoter regions within the cell nucleus. These molecules can regulate interactions between DNA sequences and transcription factors, which play a role in altering gene activation during both normal and disease-related cellular processes. This review aims to summarize the effects of AP-1-targeted decoys on various conditions. The studies demonstrated the great promising role of AP-1 decoys as therapeutics for various diseases, especially cardiovascular diseases and cancers. Moreover, it was shown that modifications of AP-1 (circular and hairpin as well as phosphorothioate backbones structures) decoys made them more stable and effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.